biostudies-literatureHuo YKey Project of Natural Science Foundation of ChinaNatural Science Foundation of Chinathe Innovative research team of high-level local universities in ShanghaiNational Key Research and Development ProgramShanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research145https://www.ebi.ac.uk/biostudies/studies/S-EPMC7923532biostudies-literatureUnknown22(1)<h4>Background</h4>Bi-specific T-cell engager (BiTE) antibody is a class of bispecific antibodies designed for cancer immunotherapy. Blinatumomab is the first approved BiTE to treat acute B cell lymphoblastic leukemia (B-ALL). It brings killer T and target B cells into close proximity, activating patient's autologous T cells to kill malignant B cells via mechanisms such as cytolytic immune synapse formation and inflammatory cytokine production. However, the activated T-cell subtypes and the target cell-dependent T cell responses induced by blinatumomab, as well as the mechanisms of resistance to blinatumomab therapy are largely unknown.<h4>Results</h4>In this study, we performed single-cell sequencing analysis to identify transcriptional changes in T cells following blinatumomab-induced T BMC genomicsBlinatumomab-induced T cell activation at single cell transcriptome resolution.PMC79235322016YFC090280081530006818701122019CXJQ01Lu DRYin HLi CMSheng ZEllwanger DCHuo YWang SHomann ORen RfalseBlinatumomab-induced T cell activation at single cell transcriptome resolution.<h4>Background</h4>Bi-specific T-cell engager (BiTE) antibody is a class of bispecific antibodies designed for cancer immunotherapy. Blinatumomab is the first approved BiTE to treat acute B cell lymphoblastic leukemia (B-ALL). It brings killer T and target B cells into close proximity, activating patient's autologous T cells to kill malignant B cells via mechanisms such as cytolytic immune synapse formation and inflammatory cytokine production. However, the activated T-cell subtypes and the target cell-dependent T cell responses induced by blinatumomab, as well as the mechanisms of resistance to blinatumomab therapy are largely unknown.<h4>Results</h4>In this study, we performed single-cell sequencing analysis to identify transcriptional changes in T cells following blinatumomab-induced T 2021-01-01T00:00:00Z2021 Mar2026-05-01T11:17:32.666Z2021-03-05T09:12:15ZS-EPMC79235323364845810.1186/s12864-021-07435-2